Thank you for joining Novel Format Conjugates!

We hope you can join your peers in person at World ADC San Diego (September 6 – 9, 2022)

Supercharging the Drug Development of Alternative Format Drug Conjugates to Maximize the Therapeutic Window & Efficacy

Welcome to the Novel Format Conjugates Summit

Built with Genentech, AstraZeneca, Starpharma, Avidity, and Guardian Therapeutics, 80+ key leaders and decision makers converged to reimagine traditional ADCs and discuss their novel format technologies.

The inaugural Novel Format Conjugates Summit exclusively focused on the common challenges across early research and development of next generation Non-Traditional ‘ADCs’, or alternative format conjugates approaches for oncology and beyond. This meeting delved into the different technologies of these novel-format conjugates, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities, and the impact an alternative format ADC has on targeting.

As we look to the future of drug development of novel conjugates, attendees heard the cutting-edge science accelerating the development of Bispecific ADCs, Radio-conjugates, ISACs, SMDCs, Probody conjugates, Liposomal drug conjugates, Oligonucleotide conjugates and many more.

Attendees engaged in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days, and equipped themselves with the tools to develop novel format ADCs with an improved therapeutic potential - to meet the aim of bringing more drugs to patients of unmet needs.

The 2022 Speaker Faculty Included:

Gavin Bennet

Head of Pre-Clinical Development

Bicycle Therapeutics

Jarrod Longcor

Chief Business Officer & SVP of Operations

Cellectar Biosciences

Ramana Doppalapudi

Vice President of Chemistry

Avidity Biosciences

Shelley Ackerman

Associate Director & Project Team Lead

Bolt Biotherapeutics

Mike Wheatcroft

Chief Scientist

Telix Pharmaceuticals

Nick Yoder

Direction, Bioconjugation

Magenta Therapeutics

Robert Huang

Robert Huang

Founder & Chief Executive Officer

Coherent Biopharma

Thomas Tulip, PhD

Chief Technology Officer

Radiopharm Theranostics

Companies Who Attended Included:

Companies Attending Novel Format Conjugates Summit

Other Events in the Series: